Last reviewed · How we verify
NCT06963866: ASCTvsCAR-T
Comparing ASCT Followed by Anti-BCMA CAR-T vs. ASCT Alone in NDMM Patients Eligible for ASCT
Phase 2 trial testing autologous stem cell transplantation in Multiple Myeloma, Newly Diagnosed in 60 participants. Not yet recruiting.
30 April 2028
Quick facts
| Lead sponsor | Xuzhou Medical University |
|---|---|
| Phase | Phase 2 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 60 |
| Start date | 1 May 2025 |
| Primary completion | 30 April 2028 |
| Estimated completion | 30 April 2028 |
| Sites | 1 location across China |
Drugs / interventions tested
- autologous stem cell transplantation — full drug profile →
- CAR-T — full drug profile →
Conditions studied
- Multiple Myeloma, Newly Diagnosed — all drugs for Multiple Myeloma, Newly Diagnosed →
Sponsor
Xuzhou Medical University
Who can join
Adults 18 to 70, any sex, with Multiple Myeloma, Newly Diagnosed. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a prospective study comparing autologous hematopoietic stem cell transplantation followed by anti-BCMA CAR-T to autologous hematopoietic stem cell transplantation alone in the treatment of newly diagnosed multiple myeloma patients.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06963866
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of autologous stem cell transplantation
Trials testing the same drug.
- NCT02843074 — Elotuzumab, Lenalidomide and Dexamethasone in Treatment of Transplant-Eligible Newly Diagnosed Multiple Myeloma Patients · Phase 2 · completed
- NCT00749723 — Therapy Optimization Trial for the Treatment of Relapsed or Refractory Brain Tumors in Children · Phase 2, PHASE3 · completed
Other recruiting trials for Multiple Myeloma, Newly Diagnosed
Currently open trials in the same condition.
- NCT07106736 — MRD-Adaptive Guided Immunotherapy With CAR-T for Transplant-Ineligible Patients With Multiple Myeloma · Phase 2 · recruiting
- NCT07106710 — ASCT Combined With BCMA CAR-T and GPRC5D/CD3 BiTEs Maintenance for Transplant-Eligible Ultra-High-Risk Multiple Myeloma · Phase 2 · recruiting
- NCT06758375 — Low Dose Teclistamab in Newly Diagnosed Multiple Myeloma Patients · Phase 2 · recruiting
Other Xuzhou Medical University trials
Trials by the same sponsor.
- NCT07370064 — Clinical Study of Anti-CLL1-CD33-NKG2D Bicephali CAR-T for Relapsed/Refractory Acute Myeloid Leukemia · Phase 1, PHASE2 · not yet recruiting
- NCT07280793 — CAR-T Cell Efficacy With Molecular Imaging in Multiple Myeloma · EARLY_PHASE1 · not yet recruiting
- NCT07070960 — A Study of Anti-BCMA CAR-T Therapy in Newly Diagnosed Myeloma Patients Who Are Transplant-ineligible · NA · not yet recruiting
- NCT07070934 — CAR-T vs. Auto-SCT: Which Works Better for New Myeloma Patients? · Phase 2 · not yet recruiting
- NCT06913192 — Efficacy of Sequential BCMA CAR-T Cell Therapy Following Autologous Hematopoietic Stem Cell Transplantation in Transplan · Phase 1 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06963866 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Xuzhou Medical University
- Last refreshed: 9 May 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06963866.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing